C

Curia

End-to-end drug development and manufacturing

Director Global Supplier Quality & Compliance

Full-Time
$185k - $210k/yr
Expert
Bachelor's
Remote in USA
RemoteApproximately 20–25% travel required.
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A bachelor's degree in a bioscience field or related study is required.
  • At least 8 years of experience working in site Quality Operational leadership roles, with Quality Assurance, Regulatory Affairs, or Compliance experience in the pharmaceutical industry at United States Food and Drug Administration-regulated facilities.
  • Experience must include drugs, devices, and biologics.
  • Broad knowledge of United States and international current Good Manufacturing Practice regulations, including 21 CFR 11, 210, 211, and 820, European Union Good Manufacturing Practice, and ICH Q7.
  • Knowledge of Code of Federal Regulations and state guidelines as they apply to controlled substance activities.
  • Knowledge and practical application of state and federal regulations related to controlled substances.
  • Knowledge of pharmaceutical manufacturing and service-provider compliance processes.
  • Experience participating in or leading United States Food and Drug Administration or European Union inspections.
  • Experience creating, executing, and checking the effectiveness of Corrective and Preventive Actions.
  • Prior supervisory experience in a pharmaceutical, Contract Research Organization, or Contract Development and Manufacturing Organization environment.
  • Ability to build consensus, negotiate, influence, collaborate across internal stakeholders, and escalate issues.
  • Understanding of the importance and use of quality metrics.
  • Ability to pass a background check and drug screen; occupational health screening may also be required.
Responsibilities
  • Serve as a quality and compliance expert for manufacturing and research and development business units, including drugs, devices, and biologics.
  • Lead Curia’s global internal audit program and maintain risk-based global internal audits, driving inspection gap assessments.
  • Lead Curia’s compliance benchmarking forum.
  • Coach and train site internal auditors.
  • Oversee Center of Excellence activities.
  • Coordinate the Global Supplier Quality program, ensure site compliance, and oversee and conduct on-site supplier audits.
  • Drive quality and compliance harmonization and continual-improvement initiatives; anticipate future industry requirements and technologies and develop plans to integrate them at Curia.
  • Coordinate and oversee regulatory inspection and audit readiness at global Good Manufacturing Practice sites, and assist with review of regulatory audit responses as needed.
  • Provide on-site support during health authority inspections as needed.
  • Coordinate or perform periodic audits, risk assessments, and gap analyses at global Good Manufacturing Practice sites to identify improvement opportunities and support remediation.
  • Ensure site implementation of and compliance with internal global policies and procedures.
  • Coordinate or perform corporate audits of global Curia sites to support mutual recognition within Curia, including demonstrating control in the transfer of materials and services between Curia sites and providing evidence of site inspection for Qualified Person batch release to the European Union.
  • Develop or review quality standards, policies, and procedures and support or monitor their implementation at global Good Manufacturing Practice sites, including data integrity and sterility assurance.
  • Develop job aids and risk-assessment templates for the site self-inspection program using a risk- and quality-system-based approach.
  • Lead regulatory intelligence to monitor emerging global current Good Manufacturing Practice requirements and regulatory topics, assess risk for Curia sites, and recommend mitigation strategies.
  • Maintain current Good Manufacturing Practice compliance risk registers for each business unit and collaborate with sites on mitigation strategies.
  • Maintain a repository of regulatory inspection documents and metrics for global Good Manufacturing Practice sites, including inspection summaries and classification of observations for presentation to site and executive leadership.
  • Escalate critical or repeated inspection and audit observations or serious compliance gaps to appropriate Quality leadership.
  • Lead routine quality and compliance training initiatives for global Good Manufacturing Practice sites, partnering with site compliance leaders and subject-matter experts to ensure broad understanding and interpretation of relevant issues.
  • Perform other duties reasonably assigned in the course of business.
  • Participate in self-development activities to stay current on regulatory agency expectations and industry best practices for supplier quality.
  • Ensure timely escalation of potential issues and proposed solutions to the line manager and Site Head as appropriate.
  • Read and interpret standard operating procedures to ensure compliance and maintain up-to-date training.
  • Lead and support a team, oversee day-to-day operations, manage departmental goals, and ensure adherence to organizational policies and procedures.
  • Foster a positive work environment, provide guidance and support to team members, and evaluate performance to drive continuous improvement and achieve departmental and organizational objectives.
Desired Qualifications
  • Auditing experience is preferred.

About the company

Curia is a contract development and manufacturing organization (CDMO) that partners with pharmaceutical and biotech companies to move medical breakthroughs from concept to market. It provides end-to-end services across the drug development lifecycle, including early research, method development and validation, preformulation, material science, solid-state chemistry, and package device testing. Revenue comes from service contracts for specialized capabilities and expertise, with clients ranging from small startups to large pharma. Curia also collaborates with industry leaders to advance continuous flow development and manufacturing programs. The company differentiates itself through flexible and scalable solutions, deep scientific expertise, and state-of-the-art technology that help clients accelerate development timelines while navigating discovery to commercialization. Its goal is to enable efficient, reliable progression of drug candidates from conception through to market approval.

Company Size

1,001-5,000

Company Stage

Debt Financing

Total Funding

$132M

Headquarters

Albany, New York

Founded

1991

Get referred to Curia

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Curia expanded Glasgow sterile drug product capacity in March 2026.
  • Curia completed a $4 million sterile API upgrade in Valladolid in October 2025.
  • Curia won a 2025 CDMO Leadership Award in Global Biologics.

What critics are saying

  • Curia is closing Burlington in 2026 and cutting 81 jobs.
  • Curia is working on an out-of-court restructuring with private credit lenders.
  • Asset sales like Pace’s New Jersey lab purchase signal continued portfolio shrinkage.

What makes Curia unique

  • Curia spans discovery through commercial manufacturing across small molecules and biologics.
  • Curia manufactures mRNA and self-replicating RNA, including Replicate Bioscience’s RBI-4000.
  • Curia runs 20+ global sites with sterile fill-finish and cell-line development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Carlyle
Jan 30th, 2026
AMRI Announces Completion of Acquisition by The Carlyle Group and GTCR | Carlyle

ALBANY, N.Y. – Albany Molecular Research, Inc. (NASDAQ:AMRI), a global contract research, development and manufacturing organization working with the life sciences industry to improve patient outcomes and quality of life for more than 25 years, today announced the completion of its previously announced acquisition by affiliates of The Carlyle Group (“Carlyle”) and affiliates of GTCR LLC (“GTCR”). President and Chief Executive Officer William S. Marth will continue to lead AMRI.

BERNAMA
May 10th, 2024
BIOLOGICS SYMPOSIUM: CURIA, CARTERRA PARTNER TO ADVANCE BIOTECH RESEARCH IN PACIFIC NORTHWEST

KUALA LUMPUR, May 10 (Bernama) - Curia, a contract research, development and manufacturing organisation (CDMO) has announced a partnership with Carterra Inc in hosting a high-throughput biologics symposium slated for May 31, in Seattle, Washington.

PharmiWeb
Mar 14th, 2024
Pace® Life Sciences Acquires New Jersey Laboratory From Curia

Former Whitehouse Analytical Laboratory is Now Part of the Pace® Laboratory Network

Pakistan Press International
Feb 23rd, 2024
Curia Appoints Steve Lavezoli as Vice President, Biologics

ALBANY, N.Y., Feb. 23, 2024 (GLOBE NEWSWIRE) - Curia, a leading contract research, development and manufacturing organization, today announced it has appointed Steve Lavezoli as vice president of biologics effective Feb. 26.

Cameroon Online News
Feb 5th, 2024
Curia Receives 2024 CDMO Leadership Award

Curia was awarded based on the feedback of respondents in the Small Pharma category.